Ministry of Science & Technology (MoST) approved Rs. 33 Million for Angioplasty Balloon Catheter manufacturing facility at SMME NUST

Principal Investigator:    Dr. Murtaza Najabat Ali

NUST plans to establish the facility for the manufacturing of Percutaneous Transluminal Coronary Angioplasty (PTCA) balloon catheter. The use of balloon catheters for the angioplasty procedure has become common treatment at most of the cardiac centers in Pakistan. The cost of the imported balloon catheters is (Rs. 25,000-40,000) prohibitive.


NUST would like to contribute in this sector by lowering the cost by using the expertise for the indigenous production of balloon catheters in Pakistan. The cost of the imported balloon catheter is very high and is not affordable by the poor. The frequency of angioplasty procedure is quite higher than cardiac stenting procedure.

Dr. Murtaza Najabat Ali (HoD Biomedical Engineering and Sciences dept. SMME NUST) managed to secure Rs. 33 Million from MoST for the establishment of dedicated facility for the production of PTCA Balloon catheters.

The indigenously developed Angioplasty Balloon catheter will not only yield its availability at a lower cost for the highly frequent Angioplasty procedure. But this will also reduce the price of the whole SAVIOR stent system (developed by Dr. Murtaza Najabat Ali when he was appointed Project Director at NESCOM few years ago).

Both academia and industry will flourish by: (i) Translating/bringing academic innovative knowledge (research) into industrial sector, and (ii) By continuously improving the medical device (product) in an industrial environment with the help of academic research (know-how). In particular, this facility will be a National Asset to meet the immediate demand of the country with special emphasis on medical export to foreign nations and cut down of foreign exchange from imported medical devices.

 

 

 

Rs. 1.0 Million awarded to the project related to the development of a Functional Stent-graft relevant for the treatment of Esophageal Cancer

Principal Investigator:    Dr. Murtaza Najabat Ali

The cancer of the esophagus is the ninth most common malignancy in the world, and ranks the sixth most frequent cause of death over the world. Oesophageal stents have been in use as a relatively better palliative method for the patients suffering from advanced stage tumor and also for the relief of dysphagia. The Dysphagia is an inability to swallow or eating and is a presenting symptom of oesophageal cancer which is indicative of incurability. In the past, conventional rigid plastic tubes were used and these rigid plastic stents required dilation and were associated with an increased complication rates. Subsequently, self-expanding metal and plastic stents (SEMS and SEPS) were developed and the advantage of this design included a large diameter stent (covered or uncovered) compressed in a significantly small diameter dedicated delivery system to facilitate oral insertion.

 

This study will refine the Auxetic oesophageal stent-graft by not only providing palliation to the patient suffering from malignant oesophageal cancer having dysphagia, but (i) will also improve the lifespan of the patient and control the surrounding tumor growth, (ii) dispense targeted local chemotherapy directly from the stent surface to the neighboring tumor tissue instead of painful systemic chemotherapy procedure, (iii) program stent made of biodegradable polyurethane in a way that it will degrade after some time in order to avoid late stent complications and painful re-intervention (stent removal) procedures and (iv) will offer cost-effective palliative and (some degree of ) curative treatment modality.